Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 3/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24208950 | 0.83 | CYP1A2 (0.39) | ALDH1A1POLBHTTMAPK1TDP1 | |
| SCHEMBL22014791 | 0.80 | ALDH1A1 (0.35) | ALDH1A1ATMPOLBHTTTDP1 | |
| SCHEMBL15808607 | 0.79 | ALDH1A1 (0.54) | ALDH1A1TSHRATMPOLBHTT | |
| SCHEMBL22014802 | 0.77 | CA2 (0.37) | ALDH1A1POLBDPP4KMT2A | |
| SCHEMBL10052779 | 0.77 | ALDH1A1 (0.56) | ALDH1A1TSHRATMPOLBHTT | |
| SCHEMBL24209508 | 0.76 | GAA (0.42) | ALDH1A1TSHRPOLBHTTLMNA | |
| Hydrochloric Acid SCHEMBL721903 | 0.75 | ALDH1A1 (0.55) | ALDH1A1TSHRATMPOLBHTT | |
| SCHEMBL24209013 | 0.74 | SIGMAR1 (0.41) | ALDH1A1TSHRPOLBTP53 | |
| SCHEMBL10264089 | 0.73 | ALDH1A1 (0.56) | ALDH1A1TSHRATMPOLBHTT | |
| SCHEMBL24208975 | 0.72 | ALDH1A1 (0.45) | ALDH1A1TSHRATMPOLBHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220017516-A1 | LOX INHIBITORS | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2022-01-20 | — | — | US | disclosed |
| WO-2020099886-A1 | LOX INHIBITORS | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2020-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220017516-A1 | LOX INHIBITORS | LOXL1, LOX, LOXL2 | ALDH1A1 122/4885TSHR 3440/4885ATM 2285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.